Phenomenological Explorations of the Esketamine-Induced Transient Dissociative State - Trial NCT06133309

Timeline & Enrollment

Primary Outcome

Consciousness fluidity evaluation by Experiential phenomenological interviews

Summary

Ketamine is an anaesthetic used in low doses to treat depressive disorders. A related
 molecule, Esketamine, has recently been launched on the market for the treatment of resistant
 depression. One of the side effects of ketamine, like Esketamine, is induction of transient
 dissociative state. Dissociation has been described as disruption in continuity of conscious
 thought and emotion, cognitive processes disorganisation and an alteration in self-perception
 and environment perception. A study of healthy volunteers receiving ketamine showed that this
 state was manifested by altered sensory perceptions, with increased noise sensitivity, visual
 distortions and altered time perception. Few studies have looked at this phenomenon in the
 Esketamine context. However, it is a frequent side effect. With ketamine, it has been shown
 that anxiety associated with dissociative experience reduces the antidepressant effect.
 Benzodiazepines use for anxiolytic purposes is also thought to limit the antidepressant
 effect.
 
 It is necessary to explore the Esketamine induced transient dissociative state in order to
 clarify this state and develop therapeutic strategies. The investigators have chosen a
 phenomenological approach, which is the only way to evaluate consciousness contents and
 structures, in order to explore this state using the experiential phenomenological interview.

ICD-10 Classifications